Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 11, 2025, titled "Zydus receives approval from China s NMPA for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg".
Zydus Lifesciences Limited Press Release Nov 11 2025
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced that it received approval from China's National Medical Products Administration for Venlafaxine Extended-Release Capsules. These capsules are intended for treating various anxiety and mood disorders. This marks the first approval Zydus has obtained from the NMPA in China.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Nov 07 2025
- Press Release Nov 06 2025
- Press Release Nov 05 2025
- Press Release Nov 04 2025
- Press Release Oct 29 2025
Later from Zydus Lifesciences
- Press Release Nov 13 2025
- Press Release Nov 14 2025
- Press Release Nov 25 2025
- Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market
- Press Release Nov 26 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences